ERAS DEADLINE: SueWallSt Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
Erasca's repeated preclinical comparisons to Revolution Medicines' RMC-6236 were allegedly improper and placed the company at risk of patent and trade secret violations, costing investors over $11 per share when the truth emerged. NEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt notifies...
Erasca's repeated preclinical comparisons to Revolution Medicines' RMC-6236 were allegedly improper and placed the company at risk of patent and trade secret violations, costing investors over $11 per share when the truth emerged. NEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt notifies...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.